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Abstract 
Growth hormone deficiency (GHD) is a severe pathology that greatly affects the quality of life, 
and increases morbidity and mortality of patients owing to the augmentation of cardiovascular 
events. Treatment of GHD is challenging, mainly because there is no specific characteristic sign 
or symptom that can be used to make a clear diagnosis. There is need for an unequivocal 
diagnosis of GHD to avoid unnecessary treatment with GH, because the available provocative 
tests (GH stimulation tests) are not specific and sensitive enough, and are contraindicated in some 
patients.  
Ghrelin is an endogenous peptide that stimulates GH secretion by interacting with a G-protein-
coupled receptor named ghrelin receptor (GH secretagogue receptor 1a, GHS-R1a). Given this, a 
GH stimulation test using ghrelin or its analogues appears to be attractive. In this paper, a 
modified tripeptide first named JMV-1843 in the laboratory is briefly presented. It is potent and 
selective in stimulating the release of GH and is orally active. It has been recently 
commercialized for the diagnosis of adult growth hormone deficiency under the tradename 
Macrilen
TM
. The test using this compound appears to be reliable, well tolerated and simple.  
 
Introduction 
Adult growth hormone deficiency (AGHD) is usually caused by childhood GHD or by various 
conditions of the hypothalamus and pituitary gland resulting from tumours and their treatments, 
including surgery and irradiation [1]. AGHD results in severe morbidity associated with reduced 
quality of life, including reduced exercise tolerance as a consequence of fat mass increase, 
osteopenia, glucose intolerance and insulin resistance, as well as altered cardiovascular functions, 
which all decrease survival [2]. In the United States, approximately 60 000 people have been 
diagnosed with AGHD, while 6000 new cases are reported each year [3]. In Europe, about 51 000 
adults are estimated to have been diagnosed with GHD [4]. However, because the symptoms are 
non-specific and there is no well-defined clinical marker of GHD in adults, a method to diagnose 
AGHD is necessary.  
 
Results and Discussion 
 
The detection of GHD is challenging, because growth hormone (GH) secretion occurs 
episodically in a pulsatile pattern, and is influenced by age, gender and body mass index [5,6]. 
Consequently, the diagnosis should be based on an appropriate provocative GH stimulation test 
(GHST) using a stimulus that can rapidly induce release of GH, which can be detected in blood 
samples [7]. 
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There are six main tests for evaluating AGHD [8,9] including the insulin tolerance test (ITT), the 
combined arginine–GH-releasing hormone (ARG-GHRH) test and the glucagon test, which are 
used for adults. The ITT is considered to be the reference test, although it is limited to certain 
patients because of the risk of hypoglycaemia; patients must not have ischaemic heart disease or 
seizures [8,9]. However, all GHSTs have limitations in the diagnosis of AGHD concerning their 
sensitivity, specificity and/or reproducibility. In addition, they usually require parenteral 
administration by trained personnel, with a follow-up period in monitored facilities. 
 
Several factors influence GH release. Among them, a potent 28-amino acid acylated peptide 
named ghrelin (Figure 1) produced mainly by the stomach, was isolated and identified by Kojima 
et al. in 1999 [10]. By binding to the 7-transmembrane G-protein-coupled receptor (GHS-R1a) 
[11], ghrelin induces GH secretion. The wide range of pharmacological and physiological 
properties of ghrelin have been described [12]. 
 
Since 1996, in collaboration with Dr R. Deghenghi, Europeptides (France) and several 
laboratories in Europe, including the Universities of Milano and Torino (Italy), we have been 
involved in a European programme (Peptido, Eureka n°1923) to design and synthesize peptides   
and mimetics able to stimulate GH release. The goal of this project was to identify an active 
compound as short as possible, selective, stable and orally effective, with possible therapeutic 
applications including the diagnostic test for detection of AGHD among GH-related disorders, 
and in some non-GH-related disorders associated with the wide range of biological activities of 
ghrelin [13,14]. 
 
In our laboratory, we have synthesized a series of analogues based on compound EP-51389, a 
potent GH-releasing peptide developed by R. Deghenghi at Europeptides (Figure 1) [15]. Based 
on our previous studies on gastrin [16] and bombesin [17], we have designed and synthesized a 
series of modified peptides, among them compound JMV-1843 (Figure 1), which, according to 
its pharmacological profile, was selected for further studies [18]. 
 
The chemical characteristics of JMV-1843 reside in its C-terminal formyl-amino function that 
mimics the C-terminal amide of EP-51389, which according to our previous studies on bombesin 
analogues should confer a certain degree of oral bioavailability [17], and on a gem-diamino 
tryptophan that improves enzymatic resistance [16]. 
 
Tested in competition binding assays using LLC PK-1 cells transiently overexpressing the cloned 
hGHS-R1a human receptor [18], human pituitary glands and hypothalamic membranes 
expressing the hGHS-R1a receptor [19], compound JMV-1843 displaced 
125
I-labelled ghrelin in a 
dose-dependent manner and with high affinity. It exhibited approximately the same potency as 
ghrelin (in the 10 nM range) and the potent hexapeptide ghrelin agonist hexarelin [20], a well-
characterized potent growth hormone secretagogue (GHS). 
 
In vivo, JMV-1843 administered subcutaneously (s.c.) in rats was able to stimulate GH release 
dose dependently to the same extent as hexarelin. In dogs, JMV-1843 administered intravenously 
(i.v.) or given orally (1 mg/kg) stimulated significant GH release [18]. Compound JMV-1843 
(then named EP1572) was then given i.v. (1.0 μg/kg as a bolus) and orally (0.06, 0.125, 0.25 and 
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0.5 mg/kg body weight) to two young male volunteers. At a dose of 0.06 mg/kg body weight 
given orally, JMV-1843 induced a remarkable and prompt increase in GH levels [19, 21] that 
persisted for 3 hours. A further randomized, placebo-controlled study was conducted on 36 
healthy volunteer male participants to evaluate both the pharmacological profile and GH-
releasing activity of increasing single oral doses of JMV-1843 [22].  
 
The results of this study indicated that oral administration of JMV-1843 (0.5 mg/kg) to healthy 
male volunteers resulted in a rapid and dose-dependent release of GH, with maximal GH release 
between 50 and 75 minutes, which lasted for >2 hours after administration. A significant GH 
release was detected even at a dose of 0.125 mg/kg. 
 
No adverse effects were observed and, in contrast to ghrelin, there was only a marginal effect on 
prolactin levels, while adrenocorticotropin (ACTH), cortisol, and ghrelin levels, as well as 
plasma concentrations of glucose and insulin, were not significantly affected.  
 
Although far from being proven, this selectivity could be the consequence of the activation of 
different G proteins that modulate different intracellular signalling pathways and induce different 
biological responses and physiological processes in a given tissue. This specific G-protein 
activation could be the result of either homodimerization of the GHS-R1a or of its 
heterodimerization with another G-protein-coupled receptor expressed in the same tissue [23, 24]. 
 
According to these preliminary results, Aetherna Zentaris selected compound JMV-1843 for 
further clinical investigation in 25 hospitals around the world: 377 participants were enrolled for 
the phase 3 clinical trials of oral administration of macimorelin (JMV-1843) as a diagnostic agent 
for AGHD. 
 
Although the oral bioavailability of macimorelin is not high, the results of this multicentre study 
indicate that, at a dose of 0.5 mg/kg body weight, macimorelin was efficient in stimulating GH 
release in the blood to a level approximately 1.4-fold higher than with the ITT, and it was well 
tolerated. It was concluded that macimorelin was useful in the diagnosis of AGHD; usually after 
collection from the patients of four blood samples, at 30, 45, 60, and 90 minutes, to reduce the 
risk of false-positive results. There was no need of an extended follow-up period, and no need of 
parenteral administration [25]. 
 
The most common adverse effects associated with macimorelin, which appeared in <5% of 
patients, were a change in the sense of taste, headache, diarrhoea, nausea and fatigue. During the 
initial phase 3 clinical trial, a drug-related alteration of cardiac rhythm (QT prolongation) was 
observed in one patient, which disappeared within 24 h. This participant had been taking 
citalopram, a drug known to be associated with QT prolongation. Accordingly, the use of 
macimorelin with drugs known to induce torsades de pointes, including antipsychotic products, 
should be contraindicated. This observation required a second phase 3 clinical investigation more 
particularly oriented towards this adverse effect. Finally, a single orally administered dose of 
macimorelin (usually 0.5 mg/kg) was recognized not to represent a particular risk and to be 
acceptable. In addition, because cytochrome P450 (CYP3A4) is involved in the metabolic 
degradation of macimorelin, one should be aware of the potential for false positives when 
diagnosing AGHD in patients treated with CYP3A4 inducers. 
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In summary, these clinical trials demonstrated that orally available macimorelin was reliable in 
the diagnosis of AGHD, with minimal adverse effects when compared with the other tests 
available, and with an acceptable safety profile. Details of the phase 3 clinical trials are available 
at https://www.clinicaltrials.gov/ct2/show/NCT02558829?term=macimorelin. However, the use 
of macimorelin for young patients and for adults with extreme and morbid obesity remains to be 
demonstrated [26]. 
In December 2017, following the successful clinical trial results, the US Food and Drug 
Administration (FDA) granted their approval for commercialization of macimorelin in the USA 
and Canada, under the tradename MacrilenTM, for the diagnosis of AGHD [27]. In January 2019, 
the European Medicines Agency (EMA) also approved the marketing authorization for 
macimorelin for the diagnosis of AGHD.  
 
A summary of the most significant events that occurred during the development of JMV-1843 to 
macimorelin and Macrilen
TM
 are reported in Table 1. 
 
Conclusion 
 
Macimorelin (Macrilen
TM
) is a novel active GH secretagogue that has an interesting 
pharmacological and clinical profile for diagnosis of AGHD, with several advantages compared 
with the established tests. Macimorelin appears to provide a simple and accurate diagnosis of 
AGHD, which has remained a challenge, and which is required for identification of patients that 
need GH treatment. The diagnosis of AGHD with macimorelin is highly competitive with the 
existing tests, which lack sensitivity and selectivity, and for which the parenteral administration 
route and the follow-up after administration of the drug are restrictive. 
 
In addition, taking into account the range of biological activities of ghrelin, macimorelin can be 
envisioned in other clinical applications. These include treatment of growth retardation in 
children, and cachexia associated with chronic diseases such as AIDS and cancer. In this respect, 
a phase 1/2 study started recently, comprising an open-label clinical trial involving 24 children 
and adolescents under the age of 18 years. Macimorelin is also being used in a phase 2A clinical 
trial for the treatment of cancer-induced cachexia. However, whether or not macimorelin is 
beneficial in clinical applications other than the diagnosis of AGHD remains to be demonstrated. 
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Table 1. From compound JMV-1843 to Macimorelin/Macrilen
TM 
 
January 1996: European program Peptido (Eureka n°1923). 
1999: Design and synthesis of compound JMV-1843 [DAPP (IBMM-Montpellier, France)].  
1999–2000: In vitro pharmacological evaluations of compound JMV-1843 [DAPP (IBMM-
Montpellier, France)]; in vivo pharmacological evaluations of JMV-1843 in several species 
(University of Milano, Italy). 
June 2000: Provisional application N° 09/880,498, filed June 2000, Patent (US 6,861,409 B2 
filed June 2001), Growth Hormone Secretagogues”", Jean Martinez, Jean-Alain Fehrentz, 
Vincent Guerlavais. 
November 2001: International patent application filed (PCT/EP01/06717, WO 01/96300 A1). 
May 2002: Publication of the first results of JMV-1843 (EP1572) orally administered to humans 
(healthy volunteers). 
July 2002: Patent licensed to Ardana Bioscience. 
Filed May 2004: Patent US 7,297,681 B2, Growth Hormone Secretagogues, Jean Martinez, 
Jean-Alain Fehrentz, Vincent Guerlavais. 
April 2005: Phase 1 clinical trials of JMV-1843 (ARD-07). 
Filed February 2007: Patent US 8,192,719 B2, PCT WO2007/093820, Methods and Kits to 
Diagnose Growth Hormone Deficiency by Oral Administration of EP1572 or EP1573 
Compounds, Finn Larsen. 
May 2007: JMV-1843 (Macimorelin/Solorel) is recognized as an orphan drug by the FDA.  
July 2008: Phase 2 clinical trials. Ardana sold the licence of JMV-1843 to Æterna-Zentaris. 
2010: Start of phase 3 clinical trials of JMV-1843 (AEZS-130, Macimorelin). 
2013: Publication of phase 3 clinical trials of JMV-1843 (Solorel, Macimorelin). 
November 2013: Application for the Marketing Authorization of JMV-1843 (Macrilen
TM
) to 
FDA.  
November 2014: Rejection by FDA. 
2015: Start of confirmatory phase 3 clinical trial. 
June 2017: New application for marketing authorization to FDA  
March 2017: The European Medicines Agency (EMA) accepted the paediatric investigation plan 
(“PIP”) of Macrilen/Macimorelin. 
November 2017: European Medicines Agency (EMA) agreed to evaluate the application for the 
marketing authorization of Macrilen/Macimorelin.  
 
December 2017: The US FDA granted marketing approval for Macrilen
TM
 in the USA and 
Canada as an oral GHS receptor agonist, to be used in the diagnosis of patients with 
AGHD. 
 
January 2018: Aeterna Zentaris entered into a licence and assignment agreement with GmbH 
Strongbridge, Ireland, from which it acquired the US and Canadian rights to Macrilen™ 
(Macimorelin). 
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October 31, 2018: Novo Nordisk acquired the rights of Macrilen
TM
 (Macimorelin) in the USA 
and Canada.  
November 2018: The Committee for Medicinal Products for Human Use (CHMP) gave a 
positive opinion of Macimorelin (Macrilen
TM
). 
 
January 2019: The EMA granted marketing authorization for Macimorelin (Macrilen
TM
). 
February 2019: Phase 1/2 paediatric clinical trial initiated with Macrilen
®
 (Macimorelin) by 
Aeterna Zentaris GmbH and Novo Nordisk. 
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            Figure 1. Structure of ghrelin, hexarelin, EP-51389 and JMV-1843 
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JMV-1843 (tradename Macrilen
TM
) is a modified tripeptide, which stimulates the release of 
growth hormone (GH) by interacting with the ghrelin receptor. Macrilen
TM
 is the first orally 
available compound commercialized for diagnosing adult growth hormone deficiency (EGHD). 
The test appears to be reliable, well tolerated and simple. The story of JMV-1843 in the 
laboratory to Macrilen
TM
 in the market is summarized. 
  
 
 
 
